GRO a Human

GRO-Alpha Human Recombinant (CXCL1)
Shipped with Ice Packs
In Stock

Description

Gene Organization and Expression

GRO-alpha is encoded by the CXCL1 gene on human chromosome 4q21, clustered with CXCL2 and CXCL3 (GRO-beta and GRO-gamma) .

AspectDetailsSource
Chromosomal Locus4q21
Tissue-Specific ExpressionInduced in monocytes, fibroblasts, epithelial cells, and melanoma cell lines
Regulatory ElementsResponsive to IL-1, TNF-α, PDGF, and phorbol esters

Regulatory Complexity:

  • Constitutive expression observed in certain tumor cell lines .

  • Differential 3' UTR structures influence mRNA stability and translation efficiency .

Biological Activities and Pathophysiological Roles

GRO-alpha mediates diverse biological processes through CXCR1/2 signaling:

FunctionMechanismImplicationsSource
Neutrophil ChemotaxisDirect activation via CXCR2Inflammation and immune response
AngiogenesisPromotes endothelial cell proliferation and migrationTumor growth and wound healing
TumorigenesisAutocrine/paracrine signaling in melanoma and epithelial cancersCancer progression
Spinal Cord DevelopmentInhibits oligodendrocyte precursor migrationNervous system development

Experimental Validation:

  • Recombinant GRO-alpha (1–100 ng/mL) induces neutrophil chemotaxis in vitro .

  • Overexpression correlates with melanoma growth and metastasis .

Research Applications and Recombinant Production

GRO-alpha is widely used in studies of inflammation, cancer, and immune regulation. Recombinant production in E. coli yields a sterile, lyophilized protein suitable for biochemical assays .

ParameterSpecificationSource
Purity>97% (RP-HPLC/SDS-PAGE)
Storage-18°C (lyophilized); 4°C (reconstituted)
Activity AssaysNeutrophil chemotaxis (10–100 ng/mL effective range)

Methodological Considerations:

  • Reconstitution in 18MΩ-cm water at ≥100 µg/mL recommended to maintain bioactivity .

  • Avoid freeze-thaw cycles to prevent protein degradation .

Comparative Analysis of GRO Isoforms

GRO-alpha, GRO-beta, and GRO-gamma form a subfamily with overlapping but distinct functions:

IsoformKey DifferencesSource
GRO-alpha (CXCL1)Higher affinity for CXCR2
GRO-beta (CXCL2)90% homology to GRO-alpha; leucine substitution at position 5
GRO-gamma (CXCL3)86% homology; distinct 3' UTR structure

Functional Redundancy:

  • All isoforms bind CXCR2 but exhibit differential receptor activation kinetics .

  • GRO-beta and GRO-gamma show enhanced neutrophil activation in specific inflammatory contexts .

Product Specs

Introduction
Chemokine (C-X-C motif) ligand 1 (CXCL1), previously known as GRO1 oncogene, Neutrophil-activating protein 3 (NAP-3), and melanoma growth stimulating activity, alpha (MSGA-a), is a small cytokine belonging to the CXC chemokine family. It's secreted by human melanoma cells, exhibits mitogenic properties, and plays a role in melanoma development. CXCL1 is produced by macrophages, neutrophils, and epithelial cells, acting as a chemoattractant for neutrophils. This chemokine contributes to spinal cord development by regulating the migration of oligodendrocyte precursors and is involved in angiogenesis, inflammation, wound healing, and tumorigenesis. CXCL1 exerts its effects by interacting with the chemokine receptor CXCR2. The gene responsible for CXCL1 production is found on human chromosome 4, grouped with genes encoding other CXC chemokines.
Description
Recombinant Human GRO Alpha, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 73 amino acids. It has a molecular weight of 7811 Daltons. The purification of GRO-alpha is achieved using proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation

The product is lyophilized from a 0.2 µm filtered concentrated solution (1 mg/ml) in 20 mM phosphate buffer (PB), with a pH of 7.4 and 50 mM NaCl.

Solubility
To reconstitute the lyophilized CXCL1, it is recommended to dissolve it in sterile 18 MΩ-cm H2O at a concentration of at least 100 µg/ml. This solution can be further diluted in other aqueous solutions.
Stability
Lyophilized GRO-alpha remains stable at room temperature for up to 3 weeks; however, it is recommended to store it desiccated below -18°C. After reconstitution, CXCL1 should be stored at 4°C for 2-7 days. For long-term storage, freezing below -18°C is advised. To enhance stability during long-term storage, adding a carrier protein (0.1% HSA or BSA) is recommended. Avoid repeated freeze-thaw cycles.
Purity
The purity is determined to be greater than 97.0% using the following methods:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Biological Activity

The biological activity is evaluated based on the ability to chemoattract human peripheral blood neutrophils within a concentration range of 10.0-100.0 ng/ml.

Synonyms
Growth-regulated protein alpha, CXCL1, Melanoma growth stimulatory activity, MGSA, Neutrophil-activating protein 3, NAP-3, GRO-alpha (1-73), chemokine (C-X-C motif) ligand 1, GRO1, GROa, SCYB1, MGSA-a, MGSA alpha.
Source
Escherichia Coli.
Amino Acid Sequence
The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Ser-Val-Ala-Thr.

Q&A

What is the fundamental purpose of GRO in human genomic research?

The Gene Regulation Observatory (GRO) was established in 2020 with the core mission of moving toward a functional, base-resolved map of the non-coding genome and its regulatory functions . This initiative brings together dedicated scientists to generate foundational data and predictive models with the ultimate goal of predicting the regulatory role of each base in the human genome across various cellular states . The approach focuses on integrated flagship projects that discover and resolve functional elements while charting their interactions with transcription factors .

Unlike traditional genomic research that primarily examines coding regions, GRO's methodological approach extends to the vast non-coding regions that play critical but less understood regulatory roles in human biology. Researchers utilizing GRO data should implement multi-layer analysis protocols that incorporate both computational predictions and experimental validations to maximize the utility of these resources.

How do researchers properly scale metabolic parameters when designing human-on-chip models?

Human-on-a-chip (HOC) models require careful consideration of metabolic scaling to faithfully recapitulate human physiology. The fundamental methodology involves inducing in-vivo-like cellular metabolic rates in vitro, which is essential for creating accurate experimental models . This approach, termed "metabolically supported scaling," requires suppressing cellular basal metabolic rate (BMR) to match in-vivo levels .

Researchers should implement the following methodological approach:

  • Calculate system parameters based on a ×10⁻⁶ miniaturization of human body by total cell mass

  • Adjust fluid-to-cell ratios to practical levels while maintaining physiological fidelity

  • Control cellular metabolism through regulated glucose delivery or other metabolic regulators

  • Monitor and verify that cellular BMR matches target in-vivo levels

  • Validate system-wide pharmacokinetic parameters against known human values

This scaling methodology ensures that despite significant miniaturization, the model maintains faithful representation of macroscopic human physiology regarding cellular BMR, basic pharmacokinetics, and inter-organ scaling .

What methodological approaches are used for resolving contradictions in experimental human models?

When developing experimental human models, researchers frequently encounter contradictions in data interpretation or model behavior. These contradictions must be systematically addressed using structured methodological approaches to ensure model validity.

The DialoguE COntradiction DEtection task (DECODE) framework offers an instructive methodology for identifying and resolving contradictions . While originally developed for dialogue systems, its principles can be adapted for experimental human models:

  • Explicitly identify potential contradicting elements within the model

  • Trace supporting evidence for each element

  • Employ structured rather than unstructured approaches to contradiction analysis

  • Mark and document all elements involved in the contradiction

  • Implement systematic methods for removing contradicting factors

This approach has been shown to be more robust and generalizable than unstructured methods, particularly when dealing with out-of-distribution scenarios . In experimental human models, this translates to more reliable identification of physiological parameters that contradict expected behavior, allowing for focused refinement of the model.

How can researchers optimize inter-organ scaling in human-on-chip models to achieve physiologically relevant interactions?

Inter-organ scaling represents one of the most challenging aspects of human-on-chip research, requiring sophisticated methodological approaches to ensure physiologically relevant interactions. Successful implementation requires:

ParameterScaling ApproachValidation Method
Organ Size RatioAllometric scaling with power law adjustmentsComparison with known anatomical ratios
Metabolic ExchangeFlow rates proportional to in-vivo perfusionMeasurement of nutrient/waste exchange rates
Fluid DynamicsAdjusted Reynolds numbers at microscaleParticle tracking velocimetry
Signaling Molecule DiffusionConcentration gradients maintained despite volume changesFluorescent tracer studies
Response TimeCompensatory adjustments for reduced diffusion distancesTemporal analysis of stimulus-response curves

The most effective methodological approach requires holistic system design where modification of any particular parameter is evaluated against its effects on all others . Natural biological systems demonstrate that structures can deviate from typical physiology while still producing viable, adaptive systems . This principle should guide the development of human-on-chip models that may not replicate exact human physiology but capture essential functional relationships.

Researchers should implement comprehensive monitoring of inter-organ communication metrics and establish baseline parameters for each organ module before integration. The validation protocol must include both individual organ function tests and integrated system responses to standardized stimuli.

What are the methodological approaches to address base-resolved functional mapping of non-coding regulatory elements in the human genome?

The comprehensive mapping of non-coding regulatory elements at base resolution requires sophisticated methodological approaches that extend beyond traditional genomic analysis. The Gene Regulation Observatory (GRO) employs several integrated strategies:

  • High-throughput functional screens to identify regulatory elements

  • Massively parallel reporter assays to quantify regulatory potential

  • CRISPR-based perturbation studies to validate functional impact

  • Multi-omics integration to correlate regulatory elements with transcriptional outcomes

  • Machine learning approaches to predict regulatory function from sequence features

When implementing these approaches, researchers should establish a hierarchical experimental design that begins with broad screening methods followed by increasingly targeted validation experiments. The methodological workflow should include:

First, comprehensive identification of candidate regulatory elements through chromatin accessibility assays and evolutionary conservation analysis. Second, functional characterization through reporter assays and chromatin conformation capture techniques. Finally, validation of regulatory impact through targeted genome editing and phenotypic assessment.

This methodological sequence ensures that resources are efficiently allocated while maximizing discovery potential. The integration of computational predictions with experimental validation creates a powerful iterative process that continuously refines our understanding of the non-coding regulatory landscape .

How can researchers implement metabolically supported scaling to ensure physiological fidelity in human-on-chip models?

Metabolically supported scaling represents a critical methodological approach for ensuring that human-on-chip models accurately reflect human physiology despite significant miniaturization. The implementation requires precise control over cellular metabolic rates to match in-vivo conditions .

The comprehensive methodology includes:

  • Baseline characterization of target in-vivo metabolic rates across different tissues

  • Implementation of controlled nutrient delivery systems (particularly glucose) to regulate metabolism

  • Development of custom media formulations that induce appropriate metabolic states

  • Integration of real-time metabolic sensing technologies

  • Implementation of feedback control systems to maintain metabolic setpoints

Research has demonstrated that cellular basal metabolic rate (BMR) must be actively suppressed to match in-vivo levels, as cells in culture typically exhibit elevated metabolic activity . This suppression can be achieved through carefully regulated nutrient availability, oxygen tension control, and media supplementation with specific metabolic modulators.

The validation protocol should include:

  • Measurement of oxygen consumption rates across all tissue modules

  • Quantification of glucose uptake and lactate production

  • Assessment of ATP production pathways

  • Evaluation of mitochondrial activity

  • Comparison of all metabolic parameters with known in-vivo values

This methodological approach ensures that despite being a ×10⁻⁶ miniaturization of the human body by total cell mass, the system remains a faithful model of macroscopic human physiology regarding cellular BMR and basic pharmacokinetics .

What methodological approaches facilitate the understanding of customer intent data through People Also Ask results in academic research?

People Also Ask (PAA) data from Google represents a valuable resource for understanding research trends and identifying knowledge gaps in academic fields. This data provides insight into what questions researchers and students are asking about specific topics .

The methodological approach to leveraging PAA data in academic research includes:

  • Systematic collection of PAA questions related to the research domain

  • Classification of questions by research stage (preliminary, methodological, analytical)

  • Analysis of question patterns to identify common conceptual challenges

  • Temporal tracking of question evolution to detect emerging research interests

  • Integration of PAA insights with formal literature review findings

PAA questions appear in over 80% of English searches, typically within the first few results . For academic researchers, these results provide valuable information about search behavior patterns, query interpretation, and audience learning goals .

When implementing this methodology, researchers should:

  • Develop a standardized taxonomy for classifying research-related questions

  • Establish regular monitoring protocols to capture changing question patterns

  • Implement cross-validation between PAA-derived insights and formal academic metrics

  • Create feedback loops where research outputs address identified question patterns

This approach transforms PAA data from a simple search feature into a powerful tool for understanding research community needs and prioritizing investigative directions.

What funding mechanisms support advanced research in human experimental models and gene regulation?

Securing appropriate funding for advanced research in human experimental models and gene regulation requires strategic alignment with available opportunities. Graduate Research Opportunity (GRO) funding represents one potential pathway, providing up to $5,000 to support doctoral student dissertation research in relevant fields .

The methodological approach to securing such funding includes:

  • Clear articulation of the research problem or question

  • Detailed description of research methods

  • Specific plans for fund utilization

  • Documentation of project status and timeline

  • Alignment with funder priorities and objectives

For GRO funding specifically, eligibility criteria include admission to candidacy, an approved dissertation proposal, satisfactory academic progress, and enrollment during the funding disbursement period . The competitive nature of such funding necessitates applications to multiple funding sources while ensuring no duplication in covered expenses .

Researchers should implement a systematic approach to funding applications:

  • Maintain a database of relevant funding opportunities with deadlines

  • Develop modular proposal components that can be adapted to different applications

  • Establish internal peer review processes for proposal refinement

  • Create clear budget justifications linked to methodological necessities

  • Document preliminary results to strengthen funding applications

This methodological approach maximizes the probability of securing necessary resources while ensuring alignment between research objectives and funder expectations.

How can researchers implement a structured framework for analyzing contradictions in experimental human models?

Addressing contradictions in experimental human models requires a systematic framework that enables identification, analysis, and resolution of inconsistencies. Drawing from the DECODE approach, researchers can implement the following methodological framework :

  • Explicit contradiction identification: Systematically compare model predictions or behaviors against expected outcomes, documenting specific points of divergence

  • Evidence tracing: For each contradiction, identify and document all supporting evidence and contributing factors

  • Structured analysis: Implement pairwise comparison of contradicting elements rather than holistic assessment

  • Explainable documentation: Mark all elements involved in contradictions with clear explanatory annotations

  • Systematic resolution: Apply formal methods for contradiction removal, documenting all modifications

The structured utterance-based approach for contradiction detection has been demonstrated to be more robust and transferable to out-of-distribution scenarios than unstructured approaches . This finding challenges the common practice of applying pre-trained models without considering structural elements, particularly relevant when contradiction detection must transfer to novel experimental contexts .

Implementation of this methodology requires:

  • Development of standardized contradiction documentation templates

  • Establishment of quantitative metrics for contradiction severity

  • Creation of decision trees for contradiction resolution pathways

  • Implementation of version control systems for model modifications

  • Regular validation testing of resolved contradictions

This approach enables researchers to systematically identify and address contradictions in experimental human models, improving model reliability and research reproducibility.

Product Science Overview

Introduction

GRO-Alpha, also known as CXCL1, is a member of the CXC chemokine family. It is a proinflammatory chemokine that plays a crucial role in the immune response by mediating the migration and activation of neutrophils. The protein is also referred to as Growth-regulated oncogene-alpha (GRO-Alpha), Keratinocyte-derived chemokine (KC), and Cytokine-induced neutrophil chemoattractant-1 (CINC-1) .

Structure and Function

CXCL1 is an approximately 8 kDa protein that shares significant sequence identity with its mouse and rat counterparts. The mature form of human CXCL1 consists of 72 amino acids and is characterized by the presence of an ELR motif (Glu-Leu-Arg) at its N-terminus, which is critical for its interaction with CXC chemokine receptors, particularly CXCR2 .

Biological Role

CXCL1 is primarily involved in the recruitment and activation of neutrophils during inflammatory responses. It is produced by various cell types, including macrophages, neutrophils, and epithelial cells, in response to proinflammatory stimuli such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). The binding of CXCL1 to its receptor CXCR2 triggers a cascade of intracellular signaling events that result in the directed migration of neutrophils to sites of infection or injury .

Clinical Significance

The expression of CXCL1 is upregulated in several pathological conditions, including cancer, where it has been implicated in tumor progression and metastasis. High levels of CXCL1 have been observed in various types of human cancers, such as uterine cervical cancer, where it facilitates tumor cell malignant processes through autocrine and paracrine mechanisms . Additionally, CXCL1 has been linked to poor clinical outcomes and advanced stages of cancer .

Recombinant Production

Recombinant human CXCL1 is produced using Escherichia coli (E. coli) expression systems. The recombinant protein is typically purified to high levels of purity (>97%) and is available in both carrier-free and carrier-containing formulations. The carrier protein, often bovine serum albumin (BSA), enhances the stability and shelf-life of the recombinant protein .

Applications

Recombinant CXCL1 is widely used in research to study its role in inflammation, cancer, and other diseases. It is also utilized in various assays to investigate the chemotactic activity of neutrophils and other immune cells. The protein’s ability to induce myeloperoxidase release from neutrophils and chemoattract BaF3 mouse pro-B cells transfected with human CXCR2 are some of the key functional assays performed using recombinant CXCL1 .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.